EZH2, encoding a histone methyltransferase, is dysregulated in many cancers (Kim and Roberts, 2016), but it is unclear if the disruption of this gene in a subset of DFT1s has provided a selective advantage to this lineage (Table S3). The gene discussed is PRDM9; the disease is cancer.